Open Orphan wins contract to support European pharma giant

Paris subsidiary Venn Life Sciences to work with oncology study enrolling 750 subjects

Open Orphan executive chairman Cathal Friel: The Paris office has “allowed us to continue to grow the business by winning large, long-term contracts”.

Open Orphan executive chairman Cathal Friel: The Paris office has “allowed us to continue to grow the business by winning large, long-term contracts”.

Dublin-listed pharmaceutical services company Open Orphan has secured a long-term contract to support a major European pharmaceutical company.

The contract win with the unnamed company comes through Open Orphan’s Paris subsidiary, Venn Life Sciences, and will handle all data management, statistics and medical writing for a prospective, multicentre, longitudinal, non-interventional oncology study expected to enrol more than 750 subjects.

Please subscribe or sign in to continue reading.
only €1 first month

Insightful opinion is just a away.